Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the prognostic value of FLT3-ITD residual disease in patients with acute myeloid leukemia (AML). Dr Valk highlights the results of a study which used next-generation sequencing (NGS) to evaluate the impact of FLT3-ITD on the risk of relapse in patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.